Settlements between PBMs, States, indicate need for 'stronger medicine' to address problems, Lazarus writes

A $9.5 million settlement with 28 states announced last week by Express Scripts to resolve allegations that the company had "been pocketing money from pharmaceutical companies to steer patients into name-brand drugs" indicates the need for "some stronger medicine" to address problems in the industry, Los Angeles Times columnist David Lazarus writes.

The settlement followed similar agreements announced by CVS Caremark earlier this year and Medco Health Solutions in 2004, Lazarus writes.

According to Lazarus, state attorneys general alleged that the PBMs, which denied any wrongdoing in the settlements, "enjoyed too-cozy relationships with drug makers that resulted in money changing hands to push favored medicines" and, in some cases, "encouraged patients and their doctors to use preferred medicines but didn't pass along rebates from drug makers in the form of lower co-pays."

The settlements might "introduce some transparency to how" PBMs operate, but "accords won't necessarily change how the business works," Lazarus writes (Lazarus, Los Angeles Times, 6/1).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients